Anzeige
Meldung des Tages: Polymarket ist bereits mehr wert als Porsche oder Continental. Der Prediction-Markt explodiert!

HANSA BIOPHARMA News

Aktie
WKN:  A0M65T ISIN:  SE0002148817 US-Symbol:  HNSBF Branche:  Biotechnologie Land:  Schweden
2,864 €
+0,002 €
+0,07%
05.03.26
Depot/Watchlist
Marktkapitalisierung *
-
Streubesitz
43,36%
KGV
-5,44
Index-Zuordnung
-

HANSA BIOPHARMA News

24.09.25 - PR Newswire
Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation
Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation PR Newswire
24.09.25 - PR Newswire
Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation
Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation PR Newswire
07.01.25 - PR Newswire
Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference
Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference PR Newswire
07.01.25 - PR Newswire
Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference
Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference PR Newswire
21.05.24 - PR Newswire
Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting
Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting PR Newswire
14.12.23 - PR Newswire
Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation
Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation PR Newswire
14.12.23 - PR Newswire
Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation
Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation PR Newswire
20.04.23 - PR Newswire
Hansa Biopharma interim report January-March 2023
Hansa Biopharma interim report January-​March 2023 PR Newswire
12.09.22 - PR Newswire
The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma's Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma's Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant ...
19.07.22 - PLX
Hansa Biopharma Q2 Revenue SEK 26.4 Million
(PLX AI) – Hansa Biopharma Q2 adjusted EPS SEK -3.82.
18.07.22 - PR Newswire
Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company's antibody-cleaving enzyme technology platform
Hansa Biopharma announces $70 million non-​dilutive product finance transaction with NovaQuest to support continued development of the company's antibody-​cleaving enzyme ...
30.05.22 - PR Newswire
The Nomination Committee in Hansa Biopharma proposes Peter Nicklin as new chair of the Board of Directors at the Annual General Meeting 2022
The Nomination Committee in Hansa Biopharma proposes Peter Nicklin as new chair of the Board of Directors at the Annual General Meeting 2022 PR Newswire
26.02.22 - PR Newswire
Hansa Biopharma announces positive early access decision by French Haute Autorité de Santé to use Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
Hansa Biopharma announces positive early access decision by French Haute Autorité de Santé to use Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney ...
09.01.22 - PR Newswire
Hansa Biopharma provides business update including certain key financials
Hansa Biopharma provides business update including certain key financials PR Newswire
03.01.22 - PR Newswire
Hansa Biopharma enters into agreement with AskBio to evaluate feasibility of imlifidase as pre-treatment ahead of gene therapy in Pompe disease
Hansa Biopharma enters into agreement with AskBio to evaluate feasibility of imlifidase as pre-​treatment ahead of gene therapy in Pompe disease Collaboration to evaluate ...
21.10.21 - PLX
Hansa Biopharma Q3 Net Income SEK -148.4 Million
(PLX AI) – Hansa Biopharma Q3 revenue SEK 4.9 million. • Q3 EBIT SEK -148.2 million
15.07.21 - PLX
Hansa Biopharma Q2 Net Income SEK -132.6 Million
(PLX AI) – Hansa Biopharma Q2 revenue SEK 4.5 million. • Q2 EBIT SEK -132.4 million
01.07.21 - PR Newswire
Hansa Biopharma to host conference call to provide interim results for first half 2021 and Business Update
Hansa Biopharma to host conference call to provide interim results for first half 2021 and Business Update PR Newswire
28.06.21 - PR Newswire
Hansa Biopharma announces decision by Swedish New Therapies Council to recommend use of Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
Hansa Biopharma announces decision by Swedish New Therapies Council to recommend use of Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney ...
23.06.21 - PR Newswire
Hansa Biopharma announces study design for a US randomized, controlled trial of imlifidase in highly sensitized kidney transplant patients
Hansa Biopharma announces study design for a US randomized, controlled trial of imlifidase in highly sensitized kidney transplant patients PR Newswire

Newssuche

Videos

newspaper
04.03.26 +5,94%
ROHÖL mit Ziel MINUS 40$?!?
Fundierte Strategien für den Handel der wichtigen News in einem Seminarpaket, plus transparenter ... Mehr »